Results 211 to 220 of about 9,547,943 (379)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Celebrating milestones in cell communication and signaling: Forthcoming joint ICCNS-ARBIOCOM anniversary meeting. [PDF]

J Cell Commun Signal
Chaqour B, Perbal A, Perbal B.
europepmc   +1 more source

On the nature of wireless signal variations—I

, 1927
E.V. Appleton, J.A. Ratcliffe
openalex   +1 more source

The Coast Signal Stations and the Semaphore Telegraph [PDF]

, 1911
R. Hudleston
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks. [PDF]

Signal Transduct Target Ther
Nadhan R, Nath K, Basu S, Isidoro C, Song YS, Dhanasekaran DN.   +5 more
europepmc   +1 more source

ACCOUSTIC EFFICIENCY OF FOG-SIGNAL MACHINERY

, 1917
Louis Vessot King
openalex   +1 more source

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Science, 2008
Siân Jones, Xiaosong Zhang, D. W. Parsons, Jimmy Lin, R. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, Seung‐Mo Hong, Baojin Fu, Ming-Tseh Lin, E. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, James J. Hartigan, Douglas R. Smith, M. Hidalgo, S. Leach, A. Klein, E. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. Eshleman, S. Kern, R. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. Velculescu, K. Kinzler   +35 more
semanticscholar   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

D1 Receptor Agonist Ameliorates Synaptic and Behavioral Deficits in a <i>Shank3</i>-Deficient Mouse Model of Autism. [PDF]

MedComm (2020)
Kim JS, Han S, An M, Park J, Lee Y, Lim J, Kim SH, Jo DG.   +7 more
europepmc   +1 more source